Products for Research Use Only

Tanezumab

CAT: 0804-HY-P99221-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99221-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia[1][2].
CAS Number
880266-57-9
Product Name Alternative
RN-624; PF 4383119
UNSPSC
12352203
Target
Trk Receptor
Type
Inhibitory Antibodies
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/tanezumab.html
Purity
99.52
Solubility
10 mM in DMSO
Smiles
[Tanezumab]
Molecular Weight
(145.44 kDa)
References & Citations
[1]Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. |[2]Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10 (4) : S44. |[3]Peng T, et al., Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression. Oxid Med Cell Longev. 2022 Oct 15;2022:8445093.|[4]Haifan W, et al. Nerve growth factor monoclonal antibody Tanezumab alleviates Kashin-Beck Disease Rat pain by impacting DRG signal transduction[J]. 2023.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3